Viatris Inc. VTRS

Company Overview

Viatris Inc. is a global healthcare company focused on generic medicines, branded pharmaceuticals, complex injectables, biosimilars, and over-the-counter products. The company was formed in 2020 through the combination of Mylan N.V. and Pfizer’s Upjohn business and operates across multiple therapeutic categories including cardiovascular disease, infectious disease, immunology, oncology, central nervous system disorders, and women’s health. Viatris generates revenue primarily through the sale of generic drugs, legacy branded medicines, and specialty pharmaceutical products distributed through retail pharmacies, hospitals, wholesalers, and government healthcare systems.

The company serves patients and healthcare providers in developed and emerging markets, with a broad commercial footprint spanning North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa. Viatris positions itself as a large-scale global supplier with extensive manufacturing and supply-chain capabilities, supported by vertically integrated production assets and a diversified product portfolio. Its strategic positioning has historically emphasized affordability, global distribution scale, and lifecycle management of established pharmaceutical products.